Systematic Financial Management LP lowered its holdings in Horizon Pharma PLC (NASDAQ:HZNP) by 15.9% in the third quarter, HoldingsChannel reports. The firm owned 70,180 shares of the biopharmaceutical company’s stock after selling 13,220 shares during the period. Systematic Financial Management LP’s holdings in Horizon Pharma were worth $1,374,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HZNP. Eagle Asset Management Inc. purchased a new stake in shares of Horizon Pharma during the second quarter worth $39,795,000. BlackRock Inc. increased its position in Horizon Pharma by 3.9% during the second quarter. BlackRock Inc. now owns 13,451,246 shares of the biopharmaceutical company’s stock worth $222,753,000 after buying an additional 507,323 shares during the last quarter. Bank of America Corp DE increased its position in Horizon Pharma by 36.4% during the second quarter. Bank of America Corp DE now owns 2,315,613 shares of the biopharmaceutical company’s stock worth $38,347,000 after buying an additional 617,595 shares during the last quarter. Principal Financial Group Inc. increased its position in Horizon Pharma by 18.3% during the first quarter. Principal Financial Group Inc. now owns 555,534 shares of the biopharmaceutical company’s stock worth $7,889,000 after buying an additional 85,970 shares during the last quarter. Finally, Spark Investment Management LLC increased its position in Horizon Pharma by 566.0% during the second quarter. Spark Investment Management LLC now owns 464,200 shares of the biopharmaceutical company’s stock worth $7,687,000 after buying an additional 394,500 shares during the last quarter. Institutional investors own 88.64% of the company’s stock.

HZNP has been the topic of several analyst reports. ValuEngine raised shares of Horizon Pharma from a “hold” rating to a “buy” rating in a research report on Monday, July 30th. Jefferies Financial Group increased their target price on shares of Horizon Pharma from $21.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. Cowen reaffirmed a “buy” rating and issued a $25.00 price target on shares of Horizon Pharma in a research report on Thursday, August 9th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $25.00 price target on shares of Horizon Pharma in a research report on Thursday, August 9th. Finally, Mizuho reaffirmed a “buy” rating and issued a $18.00 price target on shares of Horizon Pharma in a research report on Wednesday, August 8th. Six equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Horizon Pharma currently has a consensus rating of “Buy” and a consensus target price of $23.25.

HZNP stock opened at $22.22 on Tuesday. Horizon Pharma PLC has a twelve month low of $12.55 and a twelve month high of $23.38. The stock has a market cap of $3.66 billion, a P/E ratio of 18.83, a PEG ratio of 1.45 and a beta of 1.29. The company has a debt-to-equity ratio of 2.06, a quick ratio of 1.86 and a current ratio of 1.94.

Horizon Pharma (NASDAQ:HZNP) last released its earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.15. Horizon Pharma had a positive return on equity of 27.14% and a negative net margin of 18.70%. The business had revenue of $325.30 million for the quarter, compared to the consensus estimate of $311.84 million. During the same period last year, the business earned $0.26 earnings per share. The firm’s revenue for the quarter was up 19.8% compared to the same quarter last year. On average, sell-side analysts predict that Horizon Pharma PLC will post 1.3 earnings per share for the current fiscal year.

In related news, Chairman Timothy P. Walbert sold 408,347 shares of Horizon Pharma stock in a transaction dated Wednesday, November 14th. The stock was sold at an average price of $21.54, for a total transaction of $8,795,794.38. Following the sale, the chairman now directly owns 650,404 shares of the company’s stock, valued at $14,009,702.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 3.90% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Horizon Pharma PLC (HZNP) Shares Sold by Systematic Financial Management LP” was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.dailypolitical.com/2018/11/20/horizon-pharma-plc-hznp-shares-sold-by-systematic-financial-management-lp.html.

Horizon Pharma Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

See Also: What are earnings reports?

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.